PLx Pharma (PLXP) Stock Rating Lowered by Raymond James
PLx Pharma (NASDAQ:PLXP) was downgraded by investment analysts at Raymond James from an “outperform” rating to a “market perform” rating in a report issued on Monday, The Fly reports.
A number of other analysts have also recently issued reports on PLXP. Zacks Investment Research cut PLx Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. ValuEngine upgraded PLx Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.
NASDAQ PLXP opened at $4.23 on Monday. The company has a debt-to-equity ratio of 1.53, a current ratio of 4.84 and a quick ratio of 4.84. PLx Pharma has a 12 month low of $1.00 and a 12 month high of $7.60. The stock has a market cap of $28.77 million, a PE ratio of -2.17 and a beta of 2.49.
In related news, major shareholder Park West Asset Management Llc purchased 397,495 shares of the firm’s stock in a transaction on Thursday, December 27th. The stock was purchased at an average price of $1.00 per share, for a total transaction of $397,495.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.22% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in PLx Pharma stock. Vanguard Group Inc lifted its position in shares of PLx Pharma Inc (NASDAQ:PLXP) by 98.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,431 shares of the biotechnology company’s stock after acquiring an additional 80,910 shares during the period. Vanguard Group Inc owned about 1.87% of PLx Pharma worth $662,000 at the end of the most recent reporting period. 24.83% of the stock is owned by hedge funds and other institutional investors.
About PLx Pharma
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.